Defunct Company
Total Trials
1
As Lead Sponsor
0
As Collaborator
Total Enrollment
57
NCT02459652
Neoadjuvant S-1 and Concurrent Radiotherapy for Borderline Resectable Pancreatic Cancer
Phase: Phase 2
Role: Collaborator
Start: Dec 28, 2012
Completion: Jul 17, 2018